{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["140(7)"],"submitter":["Vergroesen JE"],"pubmed_abstract":["<h4>Importance</h4>Recent studies suggest that the diabetes drug metformin has a protective effect on open-angle glaucoma (OAG) and age-related macular degeneration (AMD). However, studies have not addressed the critical issue of confounding by indication, and associations have not been evaluated in a large prospective cohort.<h4>Objective</h4>To determine the association between diabetes medication and the common eye diseases OAG, AMD, and cataract and to evaluate their cumulative lifetime risks in a large cohort study.<h4>Design, setting, and participants</h4>This cohort study included participants from 3 independent cohorts from the prospective, population-based Rotterdam Study between April 23, 1990, and June 25, 2014. Participants were monitored for incident eye diseases (OAG, AMD, ca"],"journal":["JAMA ophthalmology"],"pagination":["674-681"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9121302"],"repository":["biostudies-literature"],"pubmed_title":["Association of Diabetes Medication With Open-Angle Glaucoma, Age-Related Macular Degeneration, and Cataract in the Rotterdam Study."],"pmcid":["PMC9121302"],"pubmed_authors":["Ramdas WD","Kavousi M","Klaver CCW","Thee EF","Ahmadizar F","Stricker BH","Vergroesen JE","van Duijn CM"],"additional_accession":[]},"is_claimable":false,"name":"Association of Diabetes Medication With Open-Angle Glaucoma, Age-Related Macular Degeneration, and Cataract in the Rotterdam Study.","description":"<h4>Importance</h4>Recent studies suggest that the diabetes drug metformin has a protective effect on open-angle glaucoma (OAG) and age-related macular degeneration (AMD). However, studies have not addressed the critical issue of confounding by indication, and associations have not been evaluated in a large prospective cohort.<h4>Objective</h4>To determine the association between diabetes medication and the common eye diseases OAG, AMD, and cataract and to evaluate their cumulative lifetime risks in a large cohort study.<h4>Design, setting, and participants</h4>This cohort study included participants from 3 independent cohorts from the prospective, population-based Rotterdam Study between April 23, 1990, and June 25, 2014. Participants were monitored for incident eye diseases (OAG, AMD, ca","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-05-29T16:22:20.972Z","creation":"2025-05-29T16:22:20.972Z"},"accession":"S-EPMC9121302","cross_references":{"pubmed":["35587864"],"doi":["10.1001/jamaophthalmol.2022.1435"]}}